Literature DB >> 1459168

Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole.

J Nemeth1, A Varro, J Bridson, R Walker, G J Dockray.   

Abstract

The main form of gastrin in antral mucosa, the amidated heptadecapeptide G17, is generated from an inactive precursor, progastrin, by steps involving endopeptidase cleavage and amidation. Gastrin cells are normally inhibited by gastric acid and in this study we have examined how suppression of acid by treatment with omeprazole for 6-8 weeks influences gastrin production in patients with oesophagitis. Plasma concentrations of total amidated gastrins in the fasting state increased from 18 to 43 pmol l-1; assays specific for G17-immunoreactivity indicated that the plasma concentrations of this form increased from 6 to 12 pmol l-1. In endoscopic biopsies of antral mucosa there was no change with omeprazole treatment in the concentrations of total amidated gastrins, or their immediate precursors, the Gly-extended gastrins. However, assays using an antibody that reacts with progastrin, together with size exclusion chromatography, indicated that tissue progastrin concentration increased 6-fold. The data suggest a modest net increase in gastrin production with omeprazole-treatment; because the ratio of tissue concentrations of total amidated gastrins to Gly-extended gastrins did not change, it would seem that the amidating capacity of the gastrin cell was maintained. However, the increase in progastrin concentrations suggests a relative failure of the initial steps of post-translational processing, and consequently that in certain circumstances endopeptidase cleavage of progastrin may be rate limiting.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459168     DOI: 10.1111/j.1365-2362.1992.tb01423.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Processing and proliferative effects of human progastrin in transgenic mice.

Authors:  T C Wang; T J Koh; A Varro; R J Cahill; C A Dangler; J G Fox; G J Dockray
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 2.  Role of gastrin-peptides in Barrett's and colorectal carcinogenesis.

Authors:  Eduardo Chueca; Angel Lanas; Elena Piazuelo
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

3.  A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.

Authors:  S A Watson; T M Morris; A Varro; D Michaeli; A M Smith
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

4.  Correlation between serum gastrin and cellular proliferation in Barrett's esophagus.

Authors:  Daniel A Green; Carrie M Mlynarczyk; Benjamin J Vaccaro; Kristina M Capiak; Michael Quante; Charles J Lightdale; Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2011-03       Impact factor: 4.409

5.  Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.

Authors:  Judy S Wang; Andrea Varro; Charles J Lightdale; Nantaporn Lertkowit; Kristen N Slack; Michael L Fingerhood; Wei Yann Tsai; Timothy C Wang; Julian A Abrams
Journal:  Am J Gastroenterol       Date:  2009-11-10       Impact factor: 10.864

6.  Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency.

Authors:  Robert S Jackson; John W M Creemers; I Sadaf Farooqi; Marie-Laure Raffin-Sanson; Andrea Varro; Graham J Dockray; Jens J Holst; Patricia L Brubaker; Pierre Corvol; Kenneth S Polonsky; Diane Ostrega; Kenneth L Becker; Xavier Bertagna; John C Hutton; Anne White; Mehul T Dattani; Khalid Hussain; Stephen J Middleton; Thomasina M Nicole; Peter J Milla; Keith J Lindley; Stephen O'Rahilly
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 7.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.